Low-dose interleukin-2 induces clonal expansion of BACH2-repressed effector regulatory T cells following acute coronary syndrome
Open Access
- 3 June 2025
- journal article
- research article
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 4 (6) , 727-739
Abstract
Targeting inflammation in atherosclerotic cardiovascular disease remains a major unmet need. Low-dose interleukin-2 (IL-2LD) selectively increases regulatory T (Treg) cell numbers in patients with coronary artery disease. Here we combine single-cell transcriptomics and T cell receptor analyses and show that IL-2LD clonally expands effector Treg cells in patients with acute coronary syndromes. The clonally expanded Treg cells upregulate key immunosuppressive and metabolic pathways and show an increased number of predicted ligand–receptor interactions. These Treg cells also display similar predicted antigen specificities, which cluster with published sequences specific to atherosclerotic cardiovascular disease. By tracking the T cell receptors of single cells over time, we identify an inflammatory polarization of the T cell compartment after myocardial infarction, which is restrained by IL-2LD. We identify BACH2 as a repressor of the Treg effector program. However, BACH2-mediated regulation is bypassed with IL-2LD. Overall, these results lend insight into the IL-2-driven clonal expansion program in human Treg cells, with important therapeutic implications for patients with cardiovascular and other immune-mediated diseases.Keywords
Funding Information
- British Heart Foundation (RE/24/130011, RE/18/1/34212, RE/24/130011, RE/18/1/34212, CH/10/001/27642, FS/ICRF/24/26114, FS/CRTF/24/24605, IA/F/23/275046, PG/23/11508)
- British Medical Association
- Heart Research UK (RG2699/21/23, RG2699/21/23)
- Gates Cambridge Trust
- NIH Oxford-Cambridge Scholars Program
- DH | National Institute for Health Research (NIHR203312, NIHR203312)
- U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (ZIA/hl006223)
- Wellcome Trust (220268/Z/20/Z)
- Fondation Leducq (BCVD/20CVD03)
This publication has 65 references indexed in Scilit:
- Interleukin-2 immunotherapy reveals human regulatory T cell subsets with distinct functional and tissue-homing characteristicsImmunity, 2024
- Programmed Cell Death-1 (PD-1) anchoring to the GPI-linked co-receptor CD48 reveals a novel mechanism to modulate PD-1-dependent inhibition of human T cellsMolecular Immunology, 2023
- Bach2 attenuates IL-2R signaling to control Treg homeostasis and Tfr developmentCell Reports, 2021
- Tetraspanin CD53: an overlooked regulator of immune cell functionMedical Microbiology and Immunology, 2020
- TCF1 and LEF1 Control Treg Competitive Survival and Tfr Development to Prevent Autoimmune DiseasesCell Reports, 2019
- Inflammation following acute myocardial infarction: Multiple players, dynamic roles, and novel therapeutic opportunitiesPharmacology & Therapeutics, 2018
- Regulatory T Cell Migration Is Dependent on Glucokinase-Mediated GlycolysisImmunity, 2017
- Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate EnvironmentsCell Metabolism, 2017
- Notch in T Cell Differentiation: All Things ConsideredTrends in Immunology, 2015
- Inflammation in AtherosclerosisJACC, 2009